ArticleScientific reports2022
Withania somnifera (L.) Dunal whole-plant extract demonstrates acceptable non-clinical safety in rat 28-day subacute toxicity evaluation under GLP-compliance.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review.Phytotherapy research : PTR · 2026Review
- Safety Evaluation of an Aqueous Root and Leaf Extract of Ashwagandha ( Withania somnifera ).Phytotherapy research : PTR · 2026Article
- Potential Adverse Effects of Ashwagandha: A Critical Review of Preclinical and Clinical Evidence.Phytotherapy research : PTR · 2026Review
- The interplay of Ashwagandha with hormonal dynamics and gut microbiota in women with breast cancer: a tri-axial perspective.Journal of natural medicines · 2026Review
- Therapeutic advances in the fight against microbial resistance: innovative strategies and future challenges.Folia microbiologica · 2026Review
- Nonclinical Safety Evaluation of Nonmutagenic Immunogrit Following Subacute 28-Day Repeated Dose Oral Toxicity in Sprague-Dawley Rats With GLP Compliance.Journal of toxicology · 2026Article
- In vitro antiproliferative effects of green synthesized silver nanoparticles from Brassica carinata microgreens on DU-145 prostate cancer cells and In vivo safety assessment.Journal, genetic engineering & biotechnology · 2025Article
- A Comprehensive Review on Deep Eutectic Solvents: Their Current Status and Potential for Extracting Active Compounds from Adaptogenic Plants.Molecules (Basel, Switzerland) · 2024Review
- Mutagenicity and safety evaluation of Ashwagandha (Toxicology reports · 2024Article
- Sub-acute toxicity of Ashwagandha (Toxicology reports · 2023Article
- Ethnomedicinal Uses, Phytochemistry, and Anticancer Potentials of African Medicinal Fruits: A Comprehensive Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- OECD-407 Driven 28-day-repeated-dose non-clinical safety evaluation ofFrontiers in pharmacology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Withania somnifera (L.) Dunal (Ashwagandha) is widely used in Ayurveda, Unani and Siddha systems of medicines due to its therapeutic application in numerous ailments. Traditionally, the medications prepared from the plant employ only its roots and based on the currently available scientific literature, their efficacy and safety is well established. Apart from the roots, the aerial parts also contain bioactive components and correspondingly certain marketed preparations also employ the leaves of the plant. Accordingly, Ministry of Ayush, Government of India has lately issued an advisory emphasizing the need for extensive efficacy and safety profiling of leaf-based products. Consequently, we have conducted the present GLP-driven study, in which the non-clinical safety of a hydromethanolic extract of the whole plant of Withania somnifera (WSWPE) has been assessed according to OECD guideline 407. In this study Sprague Dawley rats of either sex were orally administered with WSWPE for 28-consecutive days at the doses of 100, 300 and 1000 mg/kg/day. The study also included a satellite group of animals that received WSWPE for 28-days followed by a 14-days recovery period. Withania somnifera Whole Plant Extract was found to be safe up to the dose level of 1000 mg/kg/day as no toxicologically relevant findings could be detected.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.